# US 2016/0256489 A9 · Allograft tolerance induction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256489 A9
- Document ID: US20160256489A9
- Status: Published application
- Kind: A9
- Application number: 14/210,701
- Filed: 2014-03-14
- Published: 2016-09-08
- Earliest claimed: 2013-03-15
- Assignees: The United States of America as represented by the Secretary of the Navy
- Inventors: Thomas A. Davis; Khairul Anam; Eric A. Elster; Douglas K. Tadaki
- Web page: https://patentgrep.com/patent/US20160256489A9

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 31/255: of sulfoxy acids or sulfur analogues thereof
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12N 5/0668: {Mesenchymal stem cells from other natural sources}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method inducing chimerism and allograft tolerance by co-infusion of stein/progenitor-like cells and donor cells, wherein the donor cells can be bone marrow cells. The method also comprises the conditioning comprising depletion of CD4+ and CD8+ T-cells and administration of low doses of anti-neoplastic drugs. The inventive method comprises an aspect wherein allograft tolerance is induced without systemically suppressing the immune system.

## Claims

### Claim 1

A transplantation method comprising inducing allograft tolerance and chimerism by administering to a host one or more doses of human stem/progenitor-like cells and allogeneic donor cells, wherein said allogneic donor cells are, unprocessed bone marrow, low density bone marrow cells or side population stem cells, to a host, depleting of CD4+ and CD8+ cells and administering a nonmycloablative antineoplastic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein said method also includes the addition of donor tissue wherein said donor tissue is autologous to the donor cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein said stem/progenitor-like cells are adipose-derived stem cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein said administering of one or more doses of human stem/progenitor-like cells is up to ten (10) days before or after transplantation of tissue or organ.

### Claim 5 (depends on 1)

The method of claim 1, wherein said dose of stem/progenitor-like cells is 2×107 to 10×107 cells/kg.

### Claim 6 (depends on 1)

The method of claim 1, wherein administering of said human stem/progenitor-like cells and donor cells is intravenous, subcutaneous or intradermal.

### Claim 7 (depends on 1)

The method of claim 1, wherein said donor cells are derived from cells selected from the group consisting of cord blood, committed progenitor cells, differentiated cells, vertebral body bone marrow cells, marrow cells isolated from ribs, iliac crest cells, long bone derived marrow cells, umbilical cord blood, or mobilized stem cells.

### Claim 8

(canceled)

### Claim 9 (depends on 2)

The method of claim 2, wherein administering of said human stem/progenitor-like cells is simultaneous with the administering of donor cells to up to seven (10) days prior to donor cells.

### Claim 10 (depends on 1)

The method of claim 1, wherein a stable multilineage cell chimerism is established.

### Claim 11 (depends on 1)

The method of claim 1, wherein the donor cells are autologous, allogeneic, xenogenic or chimeric to the host.

### Claim 12 (depends on 1)

The method of claim 1, wherein said method results in expanding of pre-existing Treg cell populations of donor or host.

### Claim 13 (depends on 1)

The method of claim 1, wherein said method results in reducing expression of T-cell receptors Vβ5.1, Vβ5.2 and Vβ11 by donor T-cells.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein said depleting of CD4+ and CD8+cells is by administering of anti-CD4+ and anti-CD8+ antibody.

### Claim 16 (depends on 7)

The method of claim 7, wherein said adipose cells are CD45−, CD90+ and CD105+.

### Claim 17 (depends on 1)

The method of claim 1, wherein said anti-neoplastic agent is a non-specific alkylating anti-neoplastic agent.

### Claim 18 (depends on 17)

The method of claim 17, wherein said alkylating anti-neoplastic agent is busulfan.

### Claim 19 (depends on 18)

The method of claim 18, wherein said busulfan is administered at 5 mg/kg to 1 mg/kg.
